Tenofovir amibufenamide tenofovir alafenamide for treating chronic hepatitis B: A real-world study.

Background: The efficacy and safety profile of tenofovir amibufenamide (TMF) in chronic hepatitis B (CHB) patients is not well-established.

Aim: To compare the efficacy and safety of TMF and tenofovir alafenamide (TAF) over a 48-wk period in patients with CHB.

Methods: A total of 215 subjects meeting the inclusion criteria were enrolled and divided into two groups: TMF group ( = 106) and the TAF group ( = 109).

[Celastrol down-regulates expression of P-Akt and cyclin D1 in HL-60 cells and induces apoptosis].

The aim of this study was to investigate the effect of Celastrol on induction of HL-60 cell apoptosis and its possible mechanism. The proliferative activity of HL-60 cells treated with 0.25 - 8.